Prime Medicine Statistics
Total Valuation
Prime Medicine has a market cap or net worth of $579.97 million. The enterprise value is $597.38 million.
| Market Cap | 579.97M |
| Enterprise Value | 597.38M |
Important Dates
The last earnings date was Thursday, August 6, 2026, before market open.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Prime Medicine has 177.90 million shares outstanding. The number of shares has increased by 36.42% in one year.
| Current Share Class | 177.90M |
| Shares Outstanding | 177.90M |
| Shares Change (YoY) | +36.42% |
| Shares Change (QoQ) | +0.07% |
| Owned by Insiders (%) | 14.52% |
| Owned by Institutions (%) | 49.77% |
| Float | 110.15M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 142.39 |
| Forward PS | 51.10 |
| PB Ratio | 14.52 |
| P/TBV Ratio | 14.57 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 146.67 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.05, with a Debt / Equity ratio of 2.83.
| Current Ratio | 3.05 |
| Quick Ratio | 3.00 |
| Debt / Equity | 2.83 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -373.29% and return on invested capital (ROIC) is -73.79%.
| Return on Equity (ROE) | -373.29% |
| Return on Assets (ROA) | -46.52% |
| Return on Invested Capital (ROIC) | -73.79% |
| Return on Capital Employed (ROCE) | -90.42% |
| Weighted Average Cost of Capital (WACC) | 14.21% |
| Revenue Per Employee | $27,897 |
| Profits Per Employee | -$1.29M |
| Employee Count | 146 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -13.87% in the last 52 weeks. The beta is 2.31, so Prime Medicine's price volatility has been higher than the market average.
| Beta (5Y) | 2.31 |
| 52-Week Price Change | -13.87% |
| 50-Day Moving Average | 3.26 |
| 200-Day Moving Average | 3.62 |
| Relative Strength Index (RSI) | 52.87 |
| Average Volume (20 Days) | 2,808,432 |
Short Selling Information
The latest short interest is 33.54 million, so 18.85% of the outstanding shares have been sold short.
| Short Interest | 33.54M |
| Short Previous Month | 34.73M |
| Short % of Shares Out | 18.85% |
| Short % of Float | 30.45% |
| Short Ratio (days to cover) | 7.65 |
Income Statement
In the last 12 months, Prime Medicine had revenue of $4.07 million and -$187.89 million in losses. Loss per share was -$1.09.
| Revenue | 4.07M |
| Gross Profit | -142.13M |
| Operating Income | -196.52M |
| Pretax Income | -187.89M |
| Net Income | -187.89M |
| EBITDA | -189.12M |
| EBIT | -196.52M |
| Loss Per Share | -$1.09 |
Balance Sheet
The company has $95.07 million in cash and $112.48 million in debt, with a net cash position of -$17.41 million or -$0.10 per share.
| Cash & Cash Equivalents | 95.07M |
| Total Debt | 112.48M |
| Net Cash | -17.41M |
| Net Cash Per Share | -$0.10 |
| Equity (Book Value) | 39.81M |
| Book Value Per Share | 0.22 |
| Working Capital | 65.11M |
Cash Flow
In the last 12 months, operating cash flow was -$156.05 million and capital expenditures -$797,000, giving a free cash flow of -$156.85 million.
| Operating Cash Flow | -156.05M |
| Capital Expenditures | -797,000 |
| Depreciation & Amortization | 7.40M |
| Net Borrowing | n/a |
| Free Cash Flow | -156.85M |
| FCF Per Share | -$0.88 |
Margins
| Gross Margin | n/a |
| Operating Margin | -4,824.94% |
| Pretax Margin | -4,613.11% |
| Profit Margin | n/a |
| EBITDA Margin | -9,167.33% |
| EBIT Margin | -9,525.93% |
| FCF Margin | n/a |
Dividends & Yields
Prime Medicine does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -36.42% |
| Shareholder Yield | -36.42% |
| Earnings Yield | -32.40% |
| FCF Yield | -27.04% |
Analyst Forecast
The average price target for Prime Medicine is $7.03, which is 115.64% higher than the current price. The consensus rating is "Buy".
| Price Target | $7.03 |
| Price Target Difference | 115.64% |
| Analyst Consensus | Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | 54.06% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Prime Medicine has an Altman Z-Score of -5.86 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.86 |
| Piotroski F-Score | 1 |